ASLAN Pharma and Hyundai collaborate on varlitinib in South Korea
Singapore-based biotech firm ASLAN Pharmaceuticals and Hyundai Pharm, a leading South Korean drugmaker, have entered a collaboration and license agreement to develop and commercialize ASLAN001 (varlitinib) for the treatment of cholangiocarcinoma (CCA)in South Korea.
ASLAN001 is a potentially best-in-class small molecule pan-HER inhibitor targeted for cholangiocarcinoma, an aggressive form of bile duct cancer with no approved therapy and a very poor prognosis, and is also being studied in gastric and breast cancer. Worldwide, South Korea has one of the highest prevalence rates of cholangiocarcinoma and gastric cancer, with 4,000 and 30,000 new patients diagnosed annually respectively.
Terms of the deal
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze